

Paul Kostenuik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10811252/publications.pdf>

Version: 2024-02-01

20
papers

1,828
citations

430874

18
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

2573
citing authors

#	ARTICLE	IF	CITATIONS
1	On the evolution and contemporary roles of bone remodeling. , 2021, , 727-772.		1
2	Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants. Tissue Engineering - Part A, 2018, 24, 1672-1679.	3.1	20
3	Fracture healing physiology and the quest for therapies for delayed healing and nonunion. Journal of Orthopaedic Research, 2017, 35, 213-223.	2.3	128
4	OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice. Journal of Bone and Mineral Research, 2015, 30, 1627-1640.	2.8	57
5	Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice. Journal of Bone and Mineral Research, 2014, 29, 1158-1169.	2.8	61
6	RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease. Journal of Bone and Mineral Research, 2014, 29, 843-854.	2.8	81
7	On the Evolution and Contemporary Roles of Bone Remodeling. , 2013, , 873-914.		4
8	Osteopetrosis rescue upon RANKL administration to Rankl ^{-/-} mice: A new therapy for human RANKL-dependent ARO. Journal of Bone and Mineral Research, 2012, 27, 2501-2510.	2.8	44
9	Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone, 2012, 50, 628-637.	2.9	34
10	Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5056-5062.	3.6	234
11	Tumor necrosis factor $\hat{\pm}$ and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis and Rheumatism, 2009, 60, 2644-2654.	6.7	68
12	The Evolving Systemic and Local Biomarker Milieu at Different Stages of Disease Progression in Rat Adjuvant-Induced Arthritis. Journal of Clinical Immunology, 2009, 29, 158-174.	3.8	69
13	RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF $\hat{\pm}$ or anti-IL-1 therapies. Arthritis Research and Therapy, 2009, 11, R187.	3.5	75
14	Osteoprotegerin Abrogated Cortical Porosity and Bone Marrow Fibrosis in a Mouse Model of Constitutive Activation of the PTH/PTHrP Receptor. American Journal of Pathology, 2009, 174, 2160-2171.	3.8	29
15	Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses. Journal of Immunology, 2007, 179, 7497-7505.	0.8	62
16	Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone, 2006, 39, 754-766.	2.9	398
17	RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis. Journal of Bone and Mineral Research, 2006, 21, 1946-1954.	2.8	70
18	Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis and Rheumatism, 2005, 52, 1604-1611.	6.7	58

#	ARTICLE	IF	CITATIONS
19	Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis. <i>American Journal of Pathology</i> , 2004, 164, 543-555.	3.8	130
20	Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.. <i>Current Pharmaceutical Design</i> , 2001, 7, 613-635.	1.9	205